Recombinant HSP65 protein (ab92416)
Key features and details
- Expression system: Escherichia coli
- Purity: > 90% SDS-PAGE
- Endotoxin level: < 50.000 Eu/mg
- Active: Yes
- Suitable for: WB, Functional Studies, SDS-PAGE
製品の詳細
-
製品名
Recombinant HSP65 protein
HSP65 タンパク質・ペプチド 製品一覧 -
生理活性
This product does not contain GroEL. -
精製度
> 90 % SDS-PAGE.
ab92416 is purified by Multi-step chromatography -
エンドトキシン・レベル
< 50.000 Eu/mg -
発現系
Escherichia coli -
タンパク質長
Full length protein -
Animal free
No -
由来
Recombinant -
-
生物種
Mycobacterium bovis
-
特性
Our Abpromise guarantee covers the use of ab92416 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
アプリケーション
Western blot
Functional Studies
SDS-PAGE
-
製品の状態
Liquid -
備考
This product does not contain GroEL. -
Concentration information loading...
前処理および保存
-
保存方法および安定性
Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.
Constituents: 0.01999% Monobasic dihydrogen potassium phosphate, 0.11445% Dibasic monohydrogen sodium phosphate, 0.02025% Potassium chloride, 0.8004% Sodium chloride
This product is an active protein and may elicit a biological response in vivo, handle with caution.
関連情報
-
関連性
HSP65 is a member of the HSP60 family of heat shock proteins isolated from Mycobacterium bovis BCG. HSP65 from M. bovis is identical to that of M. tuberculosis, and similar to that of M. leprae, two highly pathogenic strains of mycobacterium. HSP65 is the immunodominant antigen during mycobacterial infection and vaccination, and has been linked to the development of autoimmune adjuvant arthritis in rats.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
Datasheet download
参考文献 (1)
ab92416 は 1 報の論文で使用されています。
- Kim BJ et al. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine. Front Immunol 9:643 (2018). PubMed: 29636755